Pancreatic Cancer Risk in Prediabetes: A Systematic Meta-analysis Approach.

IF 1.7 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pancreas Pub Date : 2025-01-01 Epub Date: 2024-09-26 DOI:10.1097/MPA.0000000000002391

Akhil Jain, Praneeth Reddy Keesari, Yashwitha Sai Pulakurthi, Rewanth Katamreddy, Meekoo Dhar, Rupak Desai

{"title":"Pancreatic Cancer Risk in Prediabetes: A Systematic Meta-analysis Approach.","authors":"Akhil Jain, Praneeth Reddy Keesari, Yashwitha Sai Pulakurthi, Rewanth Katamreddy, Meekoo Dhar, Rupak Desai","doi":"10.1097/MPA.0000000000002391","DOIUrl":null,"url":null,"abstract":"Objectives: Pancreatic cancer and prediabetes pose significant public health challenges. Given the lack of strong evidence we performed a meta-analysis to assess the risk of pancreatic cancer in prediabetes.Materials and methods: We performed a thorough search of the major databases over the last 10 years to identify relevant articles. The pooled odds ratio (OR) and hazard ratio (HR) were combined to calculate the effect size (ES).Results: We analyzed 5 studies including 5,425,111 prediabetic individuals and 16,096,467 normoglycemic population across 5 countries with a median follow-up of 8.5 years. We identified a noteworthy association between prediabetes and pancreatic cancer, reporting an unadjusted ES of 1.36 (95% confidence interval [CI] 1.05-1.77, P = 0.02) and an adjusted ES of 1.40 (1.23-1.59, P < 0.01). Subgroup analyses by age revealed variations in risk, with studies involving participants aged 60 and above exhibiting a higher ES (ES 1.83, 95% CI 1.28-2.62, P < 0.01). Geographical differences were also observed, with Japanese studies reporting a higher risk (ES 1.89, 95% CI 1.15-3.10, P < 0.01) compared with those from the United States (ES 1.32, 95% CI 1.13-1.53, P < 0.01).Conclusions: We identified 40% higher risk of pancreatic cancer in patients with prediabetes than those with normal blood glucose necessitating urgent attention for further research and policy change.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":"e51-e56"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPA.0000000000002391","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Pancreatic cancer and prediabetes pose significant public health challenges. Given the lack of strong evidence we performed a meta-analysis to assess the risk of pancreatic cancer in prediabetes.

Materials and methods: We performed a thorough search of the major databases over the last 10 years to identify relevant articles. The pooled odds ratio (OR) and hazard ratio (HR) were combined to calculate the effect size (ES).

Results: We analyzed 5 studies including 5,425,111 prediabetic individuals and 16,096,467 normoglycemic population across 5 countries with a median follow-up of 8.5 years. We identified a noteworthy association between prediabetes and pancreatic cancer, reporting an unadjusted ES of 1.36 (95% confidence interval [CI] 1.05-1.77, P = 0.02) and an adjusted ES of 1.40 (1.23-1.59, P < 0.01). Subgroup analyses by age revealed variations in risk, with studies involving participants aged 60 and above exhibiting a higher ES (ES 1.83, 95% CI 1.28-2.62, P < 0.01). Geographical differences were also observed, with Japanese studies reporting a higher risk (ES 1.89, 95% CI 1.15-3.10, P < 0.01) compared with those from the United States (ES 1.32, 95% CI 1.13-1.53, P < 0.01).

Conclusions: We identified 40% higher risk of pancreatic cancer in patients with prediabetes than those with normal blood glucose necessitating urgent attention for further research and policy change.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

糖尿病前期的胰腺癌风险：系统性元分析方法。

目标：胰腺癌和糖尿病前期对公共健康构成重大挑战。鉴于缺乏有力证据且存在不一致之处，我们进行了一项荟萃分析，以评估糖尿病前期患者胰腺癌的风险：我们对过去 10 年中的主要数据库进行了全面搜索，以确定相关文章。结果：我们分析了包括5,000名糖尿病前期患者在内的5项研究：我们分析了 5 项研究，其中包括 5,425,111 名糖尿病前期患者和 16,096,467 名血糖正常者，这些研究分布在 5 个国家，中位随访时间为 8.5 年。我们发现糖尿病前期与胰腺癌之间存在显著关联，未经调整的效应大小 (ES) 为 1.36 (95% CI 1.05-1.77, P = 0.02)，调整后的效应大小 (ES) 为 1.40 (1.23-1.59, P < 0.01)。按年龄进行的分组分析显示风险存在差异，涉及 60 岁及以上参与者的研究显示出更高的效应大小（ES 1.83，95% CI 1.28-2.62，P <0.01）。我们还观察到了地域差异，日本的研究报告与美国的研究报告（ES 1.32，95% CI 1.13-1.53，P <0.01）相比，风险更高（ES 1.89，95% CI 1.15-3.10，P <0.01）：我们发现，糖尿病前期患者罹患胰腺癌的风险比血糖正常者高出 40%，因此急需进一步研究和改变政策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pancreas 医学-胃肠肝病学

CiteScore

4.70

自引率

3.40%

发文量

289

审稿时长

1 months

期刊介绍： Pancreas provides a central forum for communication of original works involving both basic and clinical research on the exocrine and endocrine pancreas and their interrelationships and consequences in disease states. This multidisciplinary, international journal covers the whole spectrum of basic sciences, etiology, prevention, pathophysiology, diagnosis, and surgical and medical management of pancreatic diseases, including cancer.